Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.

British journal of clinical pharmacology - 1 Apr 2008

Bijl Monique J, Visser Loes E, Hofman Albert, Vulto Arnold G, van Gelder Teun, Stricker Bruno H Ch, van Schaik Ron H N

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Most antidepressants are metabolized by CYP2D6. The variant allele CYP2D6*4 is the main polymorphism resulting in reduced enzyme activity in Caucasians. * Reduced enzyme activity potentially leads to increased toxicity of antidepressants, but the relevance of genotyping for clinical practice is unclear. Most clinical studies suffer from small numbers of patients. WHAT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Tricyclic
Share to Body Weight

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Depressive Disorder, Major

Share to Drug Administration Schedule

Share to Drug Monitoring

Share to Netherlands

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 18070221
DOI: 10.1111/j.1365-2125.2007.03052.x
PMCID: PMC2291379

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.PMID 18070221Read ↗

Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.Semantic proximity Read ↗

Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory studySemantic proximity Read ↗

Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study.Semantic proximity Read ↗

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.Semantic proximity Read ↗

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studySemantic proximity Read ↗

Antidepressant Treatment and Altered CYP2D6 ActivitySemantic proximity Read ↗

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.Semantic proximity Read ↗

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.Semantic proximity Read ↗

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).Semantic proximity Read ↗

The association between CYP2D6 genotype and switching antipsychotic medication to clozapine.Semantic proximity Read ↗

Exploring the role of drug-metabolising enzymes in antidepressant side effects.Semantic proximity Read ↗

Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.